The PM Society’s ‘Is Pharma Marketing built on Straw, Sticks, or Bricks?’ interactive information afternoon, held at The Royal Society of Medicine in London on Tuesday 6th December, set out
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh